Physicians' Academy for Cardiovascular Education

BET Inhibition

BET bromodomain inhibition is an epigenetic mechanism that can modify gene transcription. BET inhibitors selective for BRD4-BD2 are currently tested in clinical trials with potentially important benefits for patients with diseases such as cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease.

Managing Diabetes & CVD: Is epigenetics a new way forward?

Aug. 25, 2017 - Barcelona, Spain

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

Meeting Impression: A novel approach for high CV risk patients with diabetes: The potential for epigenetics

Sep. 6, 2016 - news

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease

June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

Epigenetics: A closer look at BET inhibition

Sep. 5, 2016

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

Aug. 28, 2016 - ESC 2016, Rome - Jorge Plutzky, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA - Recorded at PACE-CME symposium at ESC 2016

BET inhibition in cardiovascular disease: A new dawn?

Aug. 28, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands - Recorded at PACE-CME symposium at ESC 2016

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

Aug. 28, 2016 - ESC 2016, Rome - Kausik Ray, MD – Imperial College London, United Kingdom - Recorded at PACE-CME symposium at ESC 2016

Managing Diabetes & CVD: Is epigenetics a new way forward?

Aug. 25, 2017 - Barcelona, Spain

EBAC-accredited symposium to be held during ESC 2017 in Barcelona, Spain

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada
Epigenetic apabetalone or RVX-208 that alters chromatin structure and gene activity gave clinical benefit in phase 2 study.

AHA 2016 The orally active epigenetic drug RVX-208 or apabetalone that alters gene activity by modifying chromatin structure, lowered the incidence of MACE in a phase 2b study. This effect could not entirely be attributed to an effect on HDL, explains dr. Norman Wong.

Meeting Impression: A novel approach for high CV risk patients with diabetes: The potential for epigenetics

Sep. 6, 2016 - news
A novel Approach for high CV risk patients with diabetes: The potential for epigenetics and apabetalone

A Meeting Impression from a EBAC accredited satellite symposium held at ESC 2016 in Rome that explored a novel approach to reduce residual CV risk, namely BET inhibition

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

Aug. 28, 2016 - news

At the 'A novel approach for high cv risk patients with diabetes: the potential of epigenetics' symposium, held at the ESC Congress 2016 in Rome, Kausik Ray spoke about therapeutic targets to further lower CV risk.

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

Jorge Plutzky, MD - Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Aug. 28, 2016 - Jorge Plutzky, MD - Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

At the 'A novel approach for high cv risk patients with diabetes: the potential of epigenetics' symposium, held at the ESC Congress 2016 in Rome, Jorge Plutzky spoke about BET inhibition as a nover pathway for CV risk reduction.

Effects of novel BET-inhibitor on the HDL lipidome and glucose metabolism

May 26, 2016 - Siebel AL et al., J. metabol. 2016

RVX-208 affected HDL lipid composition and HDL particle size distribution and modulated glucose metabolism in prediabetic individuals.

A novel epigenetic approach to reduce atherosclerosis

Nov. 11, 2015 - Nikolic D et al., Expert Opin Investig Drugs. 2015

RVX-208 is an investigational BET bromodomain inhibitor that upregulates apoA-I gene transcription, leading to increased HDL-levels and larger HDL particles. This review summarises currently available data.